Morgan Stanley keeps USD 240.00 target for Danaher stock

Published on 10/13/2026 at 17:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 6.26 billion, up 5.50 percent. Danaher stock costs EUR 199.13 on October 13, 2026, up 0.68 percent on Nasdaq.

Analyst target before earnings

On October 12, 2026, Morgan Stanley maintained Buy and a USD 240.00 target for Danaher.
Second-quarter revenue reached USD 6.26 billion, up 5.50 percent year over year.
Danaher stock costs EUR 199.13 at Lang & Schwarz on October 13, 2026 at 5:03 p.m. CEST, 0.68 percent above the Nasdaq prior close.
Danaher is scheduled to report third-quarter results on October 21, 2026.

Pop-Art-Comic einer begeisterten Wissenschaftlerin mit leuchtendem Reagenzglas im Retro-Halftone-Stil — Danaher Corp. Life-Sciences-Entdeckung US2358511028 als bunter Pop-Art-Comic mit Forscherin und leuchtendem Reagenzglas, Illustration mit AI erstellt.

Morgan Stanley maintained a Buy rating and a USD 240.00 target for Danaher on October 12, 2026, according to Gekko. The target lies 7.76 percent above the USD 222.72 Nasdaq price reported at 11:07 a.m. ET on October 13. At Lang & Schwarz, Danaher was trading at EUR 199.13 on October 13, 2026 at 5:03 p.m. CEST, while the Nasdaq quote was up 0.68 percent versus its USD 221.20 prior close on October 12.

Revenue growth sets the earnings backdrop

Gekko reports that Danaher generated USD 6.26 billion of revenue in the second quarter of 2026, up 5.50 percent year over year. The finance statements show USD 870.0 million of net income attributable to common shareholders and a 18.00 percent operating margin for the same quarter.

The revenue comparison matters because the next report will test whether the improvement continued beyond the June quarter. MarketBeat lists consensus expectations of USD 6.56 billion of revenue and USD 1.92 of earnings per share for the third quarter, against USD 6.05 billion and USD 1.89 in the year-earlier quarter, respectively.

Price remains below the yearly high

Danaher's Nasdaq quote stood at USD 222.72 at 11:07 a.m. ET on October 13, with a 52-week range of USD 160.93 to USD 242.80. The current level is 8.27 percent below the yearly high, calculated in US dollars from the same quote snapshot.

Trading volume was 1,377,937 shares against an average of 4,746,103 shares. Danaher is listed on the NYSE under ticker DHR, and its businesses span biotechnology, diagnostics and life sciences tools.

Valuation and the October reporting date

Danaher's market capitalization was USD 156.6 billion on October 13, 2026, while its price-to-earnings ratio was 39.61 and its trailing dividend yield was 0.01 percent. The market capitalization and valuation figures place the company among the largest listed names in medical diagnostics and research.

MarketBeat lists October 21, 2026 as Danaher's next reporting date, before the market opens, with the conference call scheduled for 8:00 a.m. ET. That date is the next defined checkpoint for the revenue and earnings expectations.

Comparison with peers

Danaher Corporation: plus 0.68 percent, P/E 39.61, market capitalization USD 156.6 billion
Thermo Fisher Scientific (NYSE, USD): minus 0.14 percent, P/E 35.63, market capitalization USD 244.5 billion
Agilent Technologies (NYSE, USD): minus 0.22 percent, P/E 33.64, market capitalization USD 48.3 billion

Danaher price at Lang & Schwarz

Danaher was trading at EUR 199.13 at Lang & Schwarz on October 13, 2026 at 5:03 p.m. CEST. The Nasdaq quote was 0.68 percent above the USD 221.20 prior close from October 12, 2026.

The further course of trading is shown by the continuously updated real-time quote of Danaher stock.